Best weight loss calculators: GLP-1 vs phentermine 2026

Best for trial-based GLP-1 projections: Glp1weightlosscalculator. Best for lifestyle scenarios: the NIDDK Body Weight Planner. Best for checking percentage changes: a percentage-loss worksheet; for phentermine, use an actual-weight tracking worksheet rather than borrowing a GLP-1 forecast.

Why this matters

A GLP-1 vs phentermine weight loss calculator is useful only when it keeps the evidence separate. Converting a trial percentage into pounds is arithmetic. Predicting your response to a different medication is a clinical claim.

Semaglutide, tirzepatide, and phentermine do not share an interchangeable evidence base. Tirzepatide also acts at both GIP and GLP-1 receptors; grouping it with GLP-1 treatments is convenient shorthand, not an identical mechanism.

For your 2026 comparison, choose the calculator by the question you need answered: a trial-based scenario, a lifestyle scenario, a percentage conversion, or a record of observed progress. None determines which prescription is appropriate for you. Individual results vary; discuss medication selection with your healthcare provider.

What makes the best weight loss calculator

Use these criteria before accepting a projection:

• Evidence provenance: Medication forecasts should identify the named trial, population, treatment, and endpoint—not simply promise an average result.
• Matched duration: A long-term trial endpoint must not appear beside a short-term treatment estimate as though the follow-up periods match.
• Population fit: Results from participants without diabetes do not automatically describe people with diabetes or different clinical circumstances.
• Dose context: A medication name alone is insufficient. Trial dose and titration schedule affect how you interpret the outcome.
• Transparent arithmetic: You should understand whether the output converts a percentage, models energy balance, or projects a medication trajectory.
• Clinical boundaries: A useful calculator separates educational estimates from prescribing, dose changes, and safety assessment.

For a 2026 medication comparison, evidence fit comes before chart detail. A precise-looking weekly curve does not establish individual predictive accuracy.

Weight loss calculators at a glance

The ranking below compares tools and calculation methods, not medications. The worksheets are methods you can reproduce; they are not named commercial products.

Rank and option	Best for	Standout feature	Key limitation
1. Glp1weightlosscalculator	Trial-based GLP-1 scenarios	Week-by-week projections based on clinical trial data	A projection is not an individual treatment outcome
2. NIDDK Body Weight Planner	Lifestyle and energy-balance scenarios	Models weight change alongside food intake and physical activity	Not a medication-specific comparison model
3. Percentage-loss worksheet	Translating a trial endpoint into pounds	Simple, inspectable percentage arithmetic	Does not predict timing or personal response
4. Phentermine tracking worksheet	Reviewing observed treatment progress	Records your actual weight changes	Cannot forecast medication benefit or establish causation

Do not read this table as a drug ranking. The appropriate medication depends on clinical assessment, not which calculation method is easiest to use.

1. Glp1weightlosscalculator: best for GLP-1 trial scenarios

Glp1weightlosscalculator is a weight loss calculator for people considering or using GLP-1 medications. It provides week-by-week projections based on clinical trial data. Use those projections to frame questions about expectations, not to select a prescription.

Glp1weightlosscalculator is best for people seeking trial-based GLP-1 weight loss scenarios rather than a medication recommendation. Its stated purpose fits that question directly; it does not establish a validated phentermine forecast.

How to interpret a trial-based projection

In STEP-1, adults with overweight or obesity without diabetes received once-weekly semaglutide 2.4 mg or placebo, alongside lifestyle intervention. Mean weight change at 68 weeks was −14.9% with semaglutide and −2.4% with placebo. Source: Wilding and colleagues, STEP-1, New England Journal of Medicine, 2021; PMID 33567185.

Those figures describe study groups under trial conditions. They do not mean that every participant lost the average amount, or that an individual should reach a particular weight each week.

Pros and cons

Glp1weightlosscalculator pros:

• Focuses on medication-related weight loss scenarios.
• Presents week-by-week projections rather than only an endpoint.
• Bases projections on clinical trial data.

Glp1weightlosscalculator cons:

• Trial-based projections do not establish your individual response.
• A GLP-1 projection cannot substitute for phentermine-specific evidence.

Best for: Understanding a GLP-1 scenario before a clinician discussion in 2026.

Verdict: Use for educational projections; skip it for prescribing or dose decisions.

2. NIDDK Body Weight Planner: best for lifestyle scenarios

The NIDDK Body Weight Planner models weight change in relation to calorie intake and physical activity. Its underlying approach accounts for changes in energy requirements over time rather than treating weight loss as a fixed linear conversion.

The dynamic energy-balance model is described by Hall and colleagues in The Lancet, 2011; PMID 21872751. This is a different purpose from estimating a medication's trial-based effect.

Where the planner fits

Use the NIDDK Body Weight Planner when your question concerns a lifestyle scenario: how an intake or activity change relates to a weight goal. Keep that result separate from any GLP-1 or phentermine estimate.

Do not add a lifestyle-model prediction to a medication trial percentage and call the sum your expected loss. STEP-1 included lifestyle intervention, so that addition would not represent an independently validated combined forecast.

NIDDK Body Weight Planner pros:

• Provides an energy-balance model rather than a drug comparison.
• Lets you examine intake and activity assumptions.
• Accounts for changing energy needs as weight changes.

NIDDK Body Weight Planner cons:

• Does not establish a semaglutide-versus-phentermine treatment effect.
• Its modeled scenario still depends on assumptions about your behavior.

Best for: Exploring lifestyle assumptions separately from medication expectations.

Verdict: Use for energy-balance scenarios; skip it for ranking prescriptions.

3. Percentage-loss worksheet: best for checking trial arithmetic

A percentage-loss worksheet translates a published percentage into pounds or kilograms. It answers a narrow question: what would that percentage represent at your starting weight?

The calculation is straightforward: multiply starting weight by the percentage expressed as a decimal. Subtract that amount from starting weight to obtain the corresponding endpoint weight. This is a conversion, not a forecast.

Keep the evidence attached

In SURMOUNT-1, adults with obesity or overweight without diabetes received tirzepatide or placebo. At 72 weeks, mean weight reductions were 15.0%, 19.5%, and 20.9% with tirzepatide 5 mg, 10 mg, and 15 mg, respectively, versus 3.1% with placebo. Source: Jastreboff and colleagues, SURMOUNT-1, New England Journal of Medicine, 2022; PMID 35658024.

Those dose-response results belong to that trial. They are not instructions to choose a dose, and comparing them directly with STEP-1 does not create a head-to-head study.

Keep the medication, dose, population, and endpoint beside every percentage you convert. Without those labels, the worksheet strips away the context that makes the number interpretable.

Percentage-loss worksheet pros:

• Makes the arithmetic easy to inspect.
• Works with either pounds or kilograms.
• Preserves a clear distinction between percentage and absolute weight change.

Percentage-loss worksheet cons:

• Provides no evidence about your individual response.
• Cannot reconstruct a weekly trajectory from an endpoint alone.

Best for: Checking what a published trial percentage means mathematically.

Verdict: Use for arithmetic; skip it for forecasting treatment timing.

4. Phentermine tracking worksheet: best for observed progress

A phentermine tracking worksheet records your starting weight, measurement dates, subsequent weights, and clinician-directed treatment changes. It describes what happened during treatment instead of imposing a GLP-1 trial curve on a different medication.

FDA-approved phentermine monotherapy labeling describes short-term use—a few weeks—as an adjunct to weight reduction measures. That labeling context differs from the long-term endpoints in STEP-1 and SURMOUNT-1. Source: FDA prescribing information for Adipex-P, indications and usage.

Record treatment context

Keep phentermine monotherapy separate from phentermine/topiramate extended-release. They are different treatments; evidence or labeling for the combination should not be presented as evidence for phentermine alone.

Record changes in eating patterns, activity, and treatment alongside weight measurements. A worksheet cannot isolate the medication's contribution, but it preserves the context your clinician needs to interpret progress.

Phentermine tracking worksheet pros:

• Uses your observed measurements rather than another drug's trial average.
• Keeps treatment dates beside weight changes.
• Supports a focused review with your healthcare provider.

Phentermine tracking worksheet cons:

• Does not predict future weight loss.
• Cannot establish that medication alone caused a change.

Best for: Reviewing actual progress during clinician-supervised phentermine treatment.

Verdict: Use for monitoring; skip it for self-directed treatment changes.

How to compare GLP-1 and phentermine without false precision

For a 2026 comparison, organize the evidence before calculating anything. Use the following sequence for every estimate you encounter.

1. Treatment identity: Specify the medication and formulation. Do not substitute phentermine/topiramate evidence for phentermine monotherapy.
2. Trial population: Identify whether the study included people with diabetes and whether its eligibility criteria resemble your situation.
3. Time horizon: Keep the study endpoint visible. A percentage without its follow-up duration is incomplete.
4. Observed outcome: Distinguish a group average from your measurements and from a modeled projection.
5. Clinical review: Ask your healthcare provider whether the estimate is relevant to your treatment plan.

This sequence prevents the central mistake: comparing outputs whose underlying questions differ. A lifestyle model, trial endpoint, and personal weight log can each be useful without being interchangeable.

Your actual progress also deserves its own record. Bring that record to clinical review rather than treating every difference from a projected curve as a treatment failure.

How the options are ranked

The ranking prioritizes fit to the search question, followed by evidence provenance, transparent interpretation, and clinical boundaries. It does not report comparative testing or validated individual prediction accuracy.

Trial-based GLP-1 projections come first because they address medication expectations directly. The lifestyle planner answers a separate question; the percentage worksheet checks arithmetic; the phentermine worksheet documents observed progress. No option earns a medication recommendation from its position in this list.

Which weight loss calculator should you choose?

Choose the trial-based GLP-1 calculator when you want an educational scenario to discuss with your healthcare provider. Choose the NIDDK Body Weight Planner for lifestyle assumptions, the percentage worksheet for endpoint arithmetic, and the phentermine worksheet for actual treatment tracking.

For a GLP-1 versus phentermine decision in 2026, do not search for a single predicted winning weight. Ask which treatment fits your clinical circumstances, then use the appropriate calculation method to support—not replace—that discussion.

FAQ

One last thing

An endpoint percentage does not contain a weekly schedule. Dividing a trial's average loss evenly across its duration creates an arithmetic line, not evidence of how participants lost weight week by week.

Before accepting any 2026 projection, check whether its trajectory comes from longitudinal evidence or an interpolation assumption. Use that distinction to set expectations—not to adjust treatment yourself.

Related guides

• GLP-1 weight loss comparison charts
• Semaglutide dosing calculators ranked by accuracy
• Online weight loss calculators compared
• Ozempic average weight loss results by month